Victoria Galán Sánchez-Seco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Victoria Galán Sánchez-Seco has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- María Luisa Martínez-Ginés
Department of Neurology, Hospital Universitario Gregorio Marañón, 28007 Madrid, Spain
4 shared publications - Yolanda Aladro
Servicio de Neurología, Hospital Universitario de Getafe, 28905 Getafe, España
4 shared publications - Julián Benito-León
Department of Neurology, 12 de Octubre University Hospital, Madrid, Spain
3 shared publications - Lucienne Costa-Frossard
CSUR de Esclerosis Múltiple, Hospital Ramón y Cajal, 28034 Madrid, España
3 shared publications - Susana Sainz de la Maza
Multiple Sclerosis CSUR Unit, Ramon y Cajal University Hospital, Foundation for Biomedical Research of University Hospital Ramón y Cajal, Alcala University
3 shared publications - Ana Gómez-López
Department of Neurology, 12 de Octubre University Hospital, 28041 Madrid, Spain
2 shared publications
Latest Publications
- Open Access
- 13 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2184
Health-Related Quality of Life in Radiologically Isolated Syndrome Resembles Relapsing–Remitting Multiple Sclerosis
Background: Radiologically isolated syndrome (RIS) is defined by MRI findings that are suggestive of multiple sclerosis (MS) in the absence of prior clinical demyelinating events. We aimed to compare the health-related quality of life (HRQoL) between RIS and relapsing–remitting MS (RRMS) after adjusting for fatigue, cognition, and psychological distress, and to contextualize generic HRQoL, relative to healthy controls. Methods: In this cross-sectional analysis of the baseline data, 30 RIS, 29 RRMS, and 30 healthy controls were analyzed. MS-specific HRQoL (patients only) was assessed with the Functional Assessment of Multiple Sclerosis (FAMS), and generic HRQoL (all participants) was assessed with the EuroQol-5D (EQ-5D) visual analogue scale and utility index. Multi-variable linear regression models with robust (HC3) standard errors were used, adjusting for demographics, fatigue impact, cognitive performance, and psychological distress. Results: The FAMS totals were similar in RIS vs. RRMS (median 167.5 vs. 164.0; p = 0.694) and remained non-different after adjustment (β= −2.37, 95% CI −10.18 to 5.44; p = 0.544). EQ-5D outcomes showed an unadjusted gradient across groups, but adjusted differences relative to RIS were not statistically significant. Greater fatigue impact was associated with poorer HRQoL across all models (all p < 0.001). Psychological distress was associated with lower FAMS (β = −14.53; p < 0.001) but not with EQ-5D outcomes. Conclusions: HRQoL in RIS was comparable to RRMS, and fatigue impact was the most consistent correlate of poorer HRQoL.
- 13 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2184
Open AccessHealth-Related Quality of Life in Radiologically Isolated Syndrome Resembles Relapsing–Remitting Multiple Sclerosis
Background: Radiologically isolated syndrome (RIS) is defined by MRI findings that are suggestive of multiple sclerosis (MS) in the absence of prior clinical demyelinating events. We aimed to compare the health-related quality of life (HRQoL) between RIS and relapsing–remitting MS (RRMS) after adjusting for fatigue, cognition, and psychological distress, and to contextualize generic HRQoL, relative to healthy controls. Methods: In this cross-sectional analysis of the baseline data, 30 RIS, 29 RRMS, and 30 healthy controls were analyzed. MS-specific HRQoL (patients only) was assessed with the Functional Assessment of Multiple Sclerosis (FAMS), and generic HRQoL (all participants) was assessed with the EuroQol-5D (EQ-5D) visual analogue scale and utility index. Multi-variable linear regression models with robust (HC3) standard errors were used, adjusting for demographics, fatigue impact, cognitive performance, and psychological distress. Results: The FAMS totals were similar in RIS vs. RRMS (median 167.5 vs. 164.0; p = 0.694) and remained non-different after adjustment (β= −2.37, 95% CI −10.18 to 5.44; p = 0.544). EQ-5D outcomes showed an unadjusted gradient across groups, but adjusted differences relative to RIS were not statistically significant. Greater fatigue impact was associated with poorer HRQoL across all models (all p < 0.001). Psychological distress was associated with lower FAMS (β = −14.53; p < 0.001) but not with EQ-5D outcomes. Conclusions: HRQoL in RIS was comparable to RRMS, and fatigue impact was the most consistent correlate of poorer HRQoL.
- Open Access
- 5 February 2026
- Published by MDPI AG in Preprints.org
Radiologically Isolated Syndrome Carries a Multiple Sclerosis–Like Patient-Reported Burden: Disease-Specific Quality of Life Comparable to Relapsing–Remitting Multiple Sclerosis
Background: Radiologically isolated syndrome (RIS) is defined by MRI findings suggestive of multiple sclerosis (MS) in the absence of prior clinical demyelinating events. We aimed to compare health-related quality of life (HRQoL) between RIS and relapsing–remitting MS (RRMS) after adjusting for fatigue, cognition, and psychological distress, and to contextualize generic HRQoL relative to healthy controls. Methods: Data from 30 RIS, 29 RRMS, and 30 healthy controls were analyzed. MS-specific HRQoL (patients only) was assessed with the Functional Assessment of Multiple Sclerosis (FAMS), and generic HRQoL (all participants) was assessed with the EuroQol-5D (EQ-5D) visual analogue scale and utility index. Multivariable linear regression with robust (HC3) standard errors adjusted for demographics, fatigue impact, cognitive performance, and psychological distress. Results: FAMS totals were similar in RIS vs RRMS (median 167.50 vs 164.0; p=0.694) and remained non-different after adjustment (β=−2.37, 95% CI −10.18 to 5.44; p=0.544). EQ-5D outcomes showed an unadjusted gradient across groups, but adjusted differences relative to RIS were not statistically significant. Greater fatigue impact was associated with poorer HRQoL across all models (all p < 0.001). Psychological distress was associated with lower FAMS (β = -14.53; p < 0.001) but not with EQ-5D outcomes. Conclusion: HRQoL in RIS was comparable to RRMS; fatigue impact was the most consistent correlate of poorer HRQoL.
- 5 February 2026
- Published by MDPI AG in Preprints.org
Open AccessRadiologically Isolated Syndrome Carries a Multiple Sclerosis–Like Patient-Reported Burden: Disease-Specific Quality of Life Comparable to Relapsing–Remitting Multiple Sclerosis
Background: Radiologically isolated syndrome (RIS) is defined by MRI findings suggestive of multiple sclerosis (MS) in the absence of prior clinical demyelinating events. We aimed to compare health-related quality of life (HRQoL) between RIS and relapsing–remitting MS (RRMS) after adjusting for fatigue, cognition, and psychological distress, and to contextualize generic HRQoL relative to healthy controls. Methods: Data from 30 RIS, 29 RRMS, and 30 healthy controls were analyzed. MS-specific HRQoL (patients only) was assessed with the Functional Assessment of Multiple Sclerosis (FAMS), and generic HRQoL (all participants) was assessed with the EuroQol-5D (EQ-5D) visual analogue scale and utility index. Multivariable linear regression with robust (HC3) standard errors adjusted for demographics, fatigue impact, cognitive performance, and psychological distress. Results: FAMS totals were similar in RIS vs RRMS (median 167.50 vs 164.0; p=0.694) and remained non-different after adjustment (β=−2.37, 95% CI −10.18 to 5.44; p=0.544). EQ-5D outcomes showed an unadjusted gradient across groups, but adjusted differences relative to RIS were not statistically significant. Greater fatigue impact was associated with poorer HRQoL across all models (all p < 0.001). Psychological distress was associated with lower FAMS (β = -14.53; p < 0.001) but not with EQ-5D outcomes. Conclusion: HRQoL in RIS was comparable to RRMS; fatigue impact was the most consistent correlate of poorer HRQoL.
- Open Access
Classification of Radiologically Isolated Syndrome and Clinically Isolated Syndrome with Machine-Learning Techniques
Background and purpose: The unanticipated detection by magnetic resonance imaging (MRI) in the brain of asymptomatic subjects of white matter lesions suggestive of multiple sclerosis (MS) has been named radiologically isolated syndrome (RIS). As the difference between early MS [i.e. clinically isolated syndrome (CIS)] and RIS is the occurrence of a clinical event, it is logical to improve detection of the subclinical form without interfering with MRI as there are radiological diagnostic criteria for that. Our objective was to use machine-learning classification methods to identify morphometric measures that help to discriminate patients with RIS from those with CIS. Methods: We used a multimodal 3-T MRI approach by combining MRI biomarkers (cortical thickness, cortical and subcortical grey matter volume, and white matter integrity) of a cohort of 17 patients with RIS and 17 patients with CIS for single-subject level classification. Results: The best proposed models to predict the diagnosis of CIS and RIS were based on the Naive Bayes, Bagging and Multilayer Perceptron classifiers using only three features: the left rostral middle frontal gyrus volume and the fractional anisotropy values in the right amygdala and right lingual gyrus. The Naive Bayes obtained the highest accuracy [overall classification, 0.765; area under the receiver operating characteristic (AUROC), 0.782]. Conclusions: A machine-learning approach applied to multimodal MRI data may differentiate between the earliest clinical expressions of MS (CIS and RIS) with an accuracy of 78%. Keywords: Bagging; Multilayer Perceptron; Naive Bayes classifier; clinically isolated syndrome; diffusion tensor imaging; machine-learning; magnetic resonance imaging; multiple sclerosis; radiologically isolated syndrome.
Open AccessClassification of Radiologically Isolated Syndrome and Clinically Isolated Syndrome with Machine-Learning Techniques
Background and purpose: The unanticipated detection by magnetic resonance imaging (MRI) in the brain of asymptomatic subjects of white matter lesions suggestive of multiple sclerosis (MS) has been named radiologically isolated syndrome (RIS). As the difference between early MS [i.e. clinically isolated syndrome (CIS)] and RIS is the occurrence of a clinical event, it is logical to improve detection of the subclinical form without interfering with MRI as there are radiological diagnostic criteria for that. Our objective was to use machine-learning classification methods to identify morphometric measures that help to discriminate patients with RIS from those with CIS. Methods: We used a multimodal 3-T MRI approach by combining MRI biomarkers (cortical thickness, cortical and subcortical grey matter volume, and white matter integrity) of a cohort of 17 patients with RIS and 17 patients with CIS for single-subject level classification. Results: The best proposed models to predict the diagnosis of CIS and RIS were based on the Naive Bayes, Bagging and Multilayer Perceptron classifiers using only three features: the left rostral middle frontal gyrus volume and the fractional anisotropy values in the right amygdala and right lingual gyrus. The Naive Bayes obtained the highest accuracy [overall classification, 0.765; area under the receiver operating characteristic (AUROC), 0.782]. Conclusions: A machine-learning approach applied to multimodal MRI data may differentiate between the earliest clinical expressions of MS (CIS and RIS) with an accuracy of 78%. Keywords: Bagging; Multilayer Perceptron; Naive Bayes classifier; clinically isolated syndrome; diffusion tensor imaging; machine-learning; magnetic resonance imaging; multiple sclerosis; radiologically isolated syndrome.
- 29 April 2020
- Published by Springer Nature in Journal of Neurology
- Vol. 267 (8) , 2362-2371
Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population
Background Dimethyl fumarate (DMF) tolerability and safety in multiple sclerosis (MS) has been analyzed in randomized clinical trials. Real-life studies are needed to assess possible harms of this therapy in a wider MS population. Objective To evaluate DMF tolerability, safety and persistence in MS in a real-world setting. Methods We conducted a multicenter prospective study of patients who started DMF, attended in 16 public hospitals of Spain. A specific database was elaborated to collect data on most frequent adverse events (AE). Regression models were used to analyze the effect of demographic and clinical characteristics on risk of AEs and DMF discontinuation. Results We collected data of 886 patients (2681 patients/years-exposition) with median 39.5 (IQR 23, 51.5) months on DMF exposure; 25.3% were treatment naïve and 74.7% switched to DMF from other disease-modifying therapies. DMF was discontinued in 29.9% of patients, in 13.2% due to AEs and in 13.5% to inefficacy. AEs were experienced by 71.2%, being flushing the most frequent (44.1%), 5.4% developed grade III lymphopenia, without cases of grade IV. Females showed a higher risk of flushing and gastroenteric symptoms (OR 1.49, p = 0.011; OR 1.69, p = 0.001, respectively); lymphopenia was associated with older age (OR 1.04, p < 0.001), and a higher EDSS with lymphopenia (OR 1.10, p = 0.035) and DMF withdrawal (HR 1.43, p = 0.012). No safety problems were reported. Conclusions Our findings confirm good tolerability and safety of DMF in real-world setting and suggest that women have an increased risk of AEs and higher baseline disability involves greater risk of drug discontinuation.
- 29 April 2020
- Published by Springer Nature in Journal of Neurology
- Vol. 267 (8) , 2362-2371
Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population
Background Dimethyl fumarate (DMF) tolerability and safety in multiple sclerosis (MS) has been analyzed in randomized clinical trials. Real-life studies are needed to assess possible harms of this therapy in a wider MS population. Objective To evaluate DMF tolerability, safety and persistence in MS in a real-world setting. Methods We conducted a multicenter prospective study of patients who started DMF, attended in 16 public hospitals of Spain. A specific database was elaborated to collect data on most frequent adverse events (AE). Regression models were used to analyze the effect of demographic and clinical characteristics on risk of AEs and DMF discontinuation. Results We collected data of 886 patients (2681 patients/years-exposition) with median 39.5 (IQR 23, 51.5) months on DMF exposure; 25.3% were treatment naïve and 74.7% switched to DMF from other disease-modifying therapies. DMF was discontinued in 29.9% of patients, in 13.2% due to AEs and in 13.5% to inefficacy. AEs were experienced by 71.2%, being flushing the most frequent (44.1%), 5.4% developed grade III lymphopenia, without cases of grade IV. Females showed a higher risk of flushing and gastroenteric symptoms (OR 1.49, p = 0.011; OR 1.69, p = 0.001, respectively); lymphopenia was associated with older age (OR 1.04, p < 0.001), and a higher EDSS with lymphopenia (OR 1.10, p = 0.035) and DMF withdrawal (HR 1.43, p = 0.012). No safety problems were reported. Conclusions Our findings confirm good tolerability and safety of DMF in real-world setting and suggest that women have an increased risk of AEs and higher baseline disability involves greater risk of drug discontinuation.